Testing a live tumor test for immune therapy response
Part of Cancer, Digestive system, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of cancer listed in the criteria (e.g., lung, skin, kidney, bladder, breast, or others) that your doctor plans to treat with an immune checkpoint inhibitor.
- Your cancer is advanced (stage III or IV) or has come back, or you are getting immunotherapy before surgery for early-stage breast or lung cancer.
- You are willing to have an extra biopsy (tissue sample) taken during a standard procedure or a separate biopsy just for research.
- You have not had cancer treatment within 2-4 weeks before the biopsy, unless you are newly diagnosed and haven't had treatment yet.
- You are in good enough health to have a performance status (ECOG) of 0, 1, or 2, meaning you can care for yourself and be up and about.
- If you could become pregnant, you have a negative pregnancy test and agree to use birth control.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with the drug pembrolizumab, to help your immune system fight cancer. It is for people with advanced solid tumors who have already tried standard treatments.
This study tests whether a blood test that detects tumor DNA can help guide the use of immunotherapy (nivolumab with or without relatlimab) after surgery for urothelial cancer. The goal is to see if starting immunotherapy based on the blood test results can prevent the cancer from coming back.
This trial studies how well immunotherapy might work by analyzing fresh tumor biopsies. It may help predict which treatments are best for your cancer.
This study collects blood and tumor samples to understand how well cancer immunotherapy works and what side effects may happen. It mainly helps researchers by checking “immune markers” before treatment starts, while you receive planned immune checkpoint therapy.
This trial tests a new immune cell therapy for people with advanced solid tumors (lung, liver, colorectal, or breast cancer). It aims to use your own immune cells to fight the cancer, and might help if standard treatments have stopped working.
This trial is testing a simple blood test (using white blood cells) to see if it can predict how well immunotherapy will work for people with advanced cancer. If you are starting immunotherapy soon as your first treatment, this study might help guide your care.
Hear when a new Early Stage Triple-Negative Breast Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.